Advanced treatment strategies for NSCLC brain metastasis in the new drug era

Huali Liu,Na Li,Huibo Zhang,Xiangpan Li,Qibin Song
DOI: https://doi.org/10.3760/cma.j.issn.2096-5400.2019.02.013
2019-01-01
Abstract:Non-small cell lung cancer (NSCLC) patients with brain metastasis present extremely poor prognosis. At present, local radiotherapy is still the standard treatment option for NSCLC with brain metastasis. In addition, tyrosine kinase inhibitor (TKI) brings new option for driver gene-positive NSCLC patients with brain metastasis, in which the anti-angiogenic drugs play a companionate role in the treatment of NSCLC with brain metastasis. AThere are further investigations for exploring the efficacy and safety of its combination application with radiotherapy, chemotherapy and molecular targeted therapy. The role of immune checkpoint inhibitors (ICIs) in NSCLC patients with brain metastasis, especially in driving gene-negative patients, has been attracted the researchers. In this article, wereview the progress on the therapeutic strategies for NSCLC with brain metastasis in the new drug era, and analyze the limitations of existing research and the facing challenges in the future. Key words: Non-small cell lung cancer; Brain metastases; Tyrosine kinase inhibitor; Anti-angiogenic drugs; Immune checkpoint inhibitors
What problem does this paper attempt to address?